Lymphoma

Latest News

Tafasitamab combined with lenalidomide and rituximab demonstrated a median OS of 22.4 months vs 13.9 months with placebo in patients with follicular lymphoma.
FDA Approves Tafasitamab Combo in R/R Follicular Lymphoma

June 18th 2025

Tafasitamab combined with lenalidomide and rituximab demonstrated a median OS of 22.4 months vs 13.9 months with placebo in patients with follicular lymphoma.

LYL314 Yields High, Durable Response Rates in Later-Line LBCL Therapy
LYL314 Yields High, Durable Response Rates in Later-Line LBCL Therapy

June 18th 2025

A retrospective analysis of real-world data confirmed the efficacy of axi-cel in relapsed/refractory large B-cell lymphoma, with outcomes comparable to the ZUMA-7 trial.
Real-World Axicabtagene Ciloleucel Shows Consistent Efficacy, Safety in R/R LBCL

June 17th 2025

No new safety signals were observed with liso-cel, with the therapy showing low rates of severe cytokine release syndrome and neurologic events.
Liso-Cel Exhibits High Durable Response Rates in R/R Marginal Zone Lymphoma

June 16th 2025

JNJ’4496 Demonstrates Clinical Benefit, Safety in Relapsed/Refractory LBCL
JNJ’4496 Demonstrates Clinical Benefit, Safety in Relapsed/Refractory LBCL

June 13th 2025

Latest CME Events & Activities

Medical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple Myeloma

View More

Cases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma

View More

Cases & Conversations™: Transforming AML Care—Precision Strategies, Evolving Therapies, and Clinical Insights

View More

Medical Crossfire®: Improving Patient Outcomes in Myeloproliferative Neoplasms With Novel Therapeutic Approaches

View More

Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care

View More

Community Practice Connections™: Selecting and Sequencing Therapy for Patients with DLBCL in an Era of Expanding Options

View More

BURST Expert Illustrations and Commentaries™: Exploring the Mechanistic Rationale for CSF-1R– Directed Treatment in Chronic GVHD

View More

(CME) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care

View More

(COPE) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care

View More

Community Practice Connections™: 6th Annual Precision Medicine Symposium – An Illustrated Tumor Board

View More

Medical Crossfire®: Expert Interpretations of the Latest Data in CLL Management – Understanding the Impact of Optimal Treatment Selection on Patient Outcomes

View More

Community Practice Connections™: Tailored Treatment Approaches for Older Patients With Advanced HR+/HER2– Breast Cancer

View More